Neeraj Agarwal, MD, discusses the significance of the phase 3 LATITUDE trial, which examined abiraterone acetate in patients with metastatic castration-sensitive prostate cancer.
Neeraj Agarwal, MD, a professor of medicine and director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, discusses the significance of the phase 3 LATITUDE trial, which examined abiraterone acetate (Zytiga) in patients with metastatic castration-sensitive prostate cancer (CSPC).
LATITUDE was the first trial to examine abiraterone in patients with high-risk, metastatic, CSPC, according to Agarwal. Risk status for the trial was defined by having 3 or more bone metastases, a Gleason score of 8 or higher, or visceral metastases. Patients needed to meet 2 of the 3 high-risk criteria in order to be eligible for the trial, Agarwal explains.
The use of abiraterone was found to improve radiographic progression-free survival and overall survival in this patient population; this helped to establish the idea that intensifying treatment with hormonal therapy can improve survival in patients with metastatic CSPC, Agarwal concludes.